

# Annette M Staiger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5217943/publications.pdf>

Version: 2024-02-01

22  
papers

2,639  
citations

623574

14  
h-index

642610

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

4344  
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP14 is a novel target in STAT6 mutant follicular lymphoma. <i>Leukemia</i> , 2022, 36, 2281-2292.	3.3	11
2	Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. <i>Cancers</i> , 2021, 13, 1002.	1.7	9
3	The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 575-583.	1.4	11
4	Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e267-e277.	2.2	18
5	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	38
6	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183.	5.8	26
7	Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1107-1115.	0.6	2
8	A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. <i>Leukemia</i> , 2020, 34, 543-552.	3.3	26
9	Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. <i>Blood Advances</i> , 2020, 4, 4451-4462.	2.5	8
10	Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles. <i>Blood</i> , 2020, 135, 181-190.	0.6	11
11	Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA). <i>Blood</i> , 2020, 136, 5-6.	0.6	0
12	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
13	Chromatin conformation analysis of primary patient tissue using a low input Hi-C method. <i>Nature Communications</i> , 2018, 9, 4938.	5.8	89
14	Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. <i>Blood</i> , 2017, 130, 310-322.	0.6	82
15	<i>TP53</i> mutation and survival in aggressive B cell lymphoma. <i>International Journal of Cancer</i> , 2017, 141, 1381-1388.	2.3	69
16	An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 1922-1930.	0.6	12
17	New targeted therapies for malignant lymphoma based on molecular heterogeneity. <i>Expert Review of Hematology</i> , 2017, 10, 39-51.	1.0	14
18	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. <i>Blood</i> , 2017, 129, 333-346.	0.6	57

#	ARTICLE	IF	CITATIONS
19	Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2515-2526.	0.8	179
20	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	0.6	177
21	Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for <i>MYC</i> - <i>IGH</i> Translocations. <i>American Journal of Surgical Pathology</i> , 2015, 39, 61-66.	2.1	34
22	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology</i> , The, 2015, 16, 1111-1122.	5.1	483